Enhancer of zeste homolog 2 (EZH2)-dependent sirtuin-3 determines sensitivity to glucose starvation in radioresistant head and neck cancer cells

被引:0
|
作者
Chang, Hyo Won [1 ]
Park, Jung Je [2 ]
Lee, Won Hyeok [3 ]
Kim, Song Hee [3 ]
Lee, Jong Cheol [4 ]
Nam, Hae Yun [1 ]
Kim, Mi Ra [4 ]
Han, Myung Woul [3 ]
Lee, Yoon Se [5 ]
Kim, Sang Yoon [6 ]
Kim, Seong Who [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Biochem & Mol Biol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
[2] Gyeongsang Natl Univ, Inst Hlth Sci, Coll Med, Dept Otolaryngol, Jinju, South Korea
[3] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Otolaryngol, Ulsan, South Korea
[4] Univ Ulsan, Gangneung Asan Hosp, Coll Med, Dept Otolaryngol, Kangnung, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Otolaryngol, Seoul, South Korea
[6] Pharosgen Co Ltd, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
EZH2; SIRT3; Glucose starvation; Head and neck cancer cell; Radioresistance; OXIDATIVE STRESS; BREAST-CANCER; STEM-CELLS; EZH2; SIRT3; INHIBITION; MECHANISMS; GENE; CONTRIBUTES; DEFICIENCY;
D O I
10.1016/j.cellsig.2023.111029
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Sirtuin 3 (SIRT3) regulates mitochondrial function as a mitochondrial deacetylase during oxidative stress. However, the specific regulatory mechanism and function of SIRT3 in radioresistant cancer cells are unclear. In this study, we aim to investigate how SIRT3 determines the susceptibility to glucose deprivation and its regulation in p53-based radioresistant head and neck cancer cells. We observed mitochondrial function using two established isogenic radioresistant subclones (HN3R-A [p53 null] and HN3R-B [p53 R282W]) with intratumoral p53 heterogeneity. Cell counting analysis was performed to evaluate cell proliferation and cell death. The correlation between the regulation of SIRT3 and enhancer of zeste homolog 2 (EZH2) was confirmed by immunoblotting and chromatin immunoprecipitation assay. p53-deficient radioresistant cells (HN3R-A) expression reduced SIRT3 levels and increased sensitivity to glucose deprivation due to mitochondrial dysfunction compared to other cells. In these cells, activation of SIRT3 significantly prevented glucose deprivation-induced cell death, whereas the loss of SIRT3 increased the susceptibility to glucose deficiency. We discovered that radiation-induced EZH2 directly binds to the SIRT3 promoter and represses the expression. Conversely, inhibiting EZH2 increased the expression of SIRT3 through epigenetic changes. Our findings indicate that p53 -deficient radioresistant cells with enhanced EZH2 exhibit increased sensitivity to glucose deprivation due to SIRT3 suppression. The regulation of SIRT3 by EZH2 plays a critical role in determining the cell response to glucose deficiency in radioresistant cancer cells. Therefore, EZH2-dependent SIRT3 could be used as a predictive biomarker to select treatment options for patients with radiation-resistance.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Enhancer of zeste homolog 2 (EZH2) promotes expansion of breast tumor initiation cells through activation of Notch1-jagged signaling
    Gonzalez, Maria E.
    Li, Xin
    Kruger, Heather
    Toy, Kathy
    Kleer, Celina G.
    CANCER RESEARCH, 2011, 71
  • [32] Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration and invasion in endometrial cancer cell lines
    Eskander, R.
    Ji, T.
    Huynh, B.
    Wardeh, R.
    Hoang, B.
    Randall, L.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : S5 - S5
  • [33] THE PUTATIVE TUMOR SUPPRESSOR MICRORNA-101 NEGATIVELY REGULATES THE POLYCOMB GROUP PROTEIN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) IN HUMAN HEPATOCELLULAR CARCINOMA CELLS
    Xu, L.
    Beckebaum, S.
    Wu, G.
    Zhang, X.
    Lu, M.
    Iacob, S.
    Paul, A.
    Gerken, G.
    Cicinnati, V. R.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S110 - S110
  • [34] Differential expression of microRNA, miR-150 and enhancer of zeste homolog 2 (EZH2) in peripheral blood cells as early prognostic markers of severe forms of dengue
    Harsha Hapugaswatta
    Pubudu Amarasena
    Ranjan Premaratna
    Kapila N. Seneviratne
    Nimanthi Jayathilaka
    Journal of Biomedical Science, 27
  • [35] POLYCOMB PROTEIN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) PROTECTS HUMAN HEPATOCELLULAR CARCINOMA (HCC) CELLS FROM DNA DAMAGE RESPONSE (DDR) ASSOCIATED APOPTOSIS
    Salerno, D.
    Jeddari, S.
    Belloni, L.
    Pediconi, N.
    Levrero, M.
    DIGESTIVE AND LIVER DISEASE, 2014, 46 : E38 - E38
  • [36] Differential expression of microRNA, miR-150 and enhancer of zeste homolog 2 (EZH2) in peripheral blood cells as early prognostic markers of severe forms of dengue
    Hapugaswatta, Harsha
    Amarasena, Pubudu
    Premaratna, Ranjan
    Seneviratne, Kapila N.
    Jayathilaka, Nimanthi
    JOURNAL OF BIOMEDICAL SCIENCE, 2020, 27 (01)
  • [37] Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).
    Schweizer, Michael Thomas
    Penkov, Konstantin
    Choudhury, Atish Dipankar
    Calvo, Emiliano
    Frank, Richard C.
    Liu, Li
    Mittapalli, Rajendar K.
    Tougias, Jessica
    Andreu-Vieyra, Claudia
    Bowler, Timothy Geoffrey
    Soman, Neelesh
    Garmezy, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
    Kung, Pei-Pei
    Rui, Eugene
    Bergqvist, Simon
    Bingham, Patrick
    Braganza, John
    Collins, Michael
    Cui, Mei
    Diehl, Wade
    Dac Dinh
    Fan, Connie
    Fantin, Valeria R.
    Gukasyan, Hovhannes J.
    Hu, Wenyue
    Huang, Buwen
    Kephart, Susan
    Krivacic, Cody
    Kumpf, Robert A.
    Li, Gary
    Maegley, Karen A.
    McAlpine, Indrawan
    Nguyen, Lisa
    Ninkovic, Sacha
    Ornelas, Martha
    Ryskin, Michael
    Scales, Stephanie
    Sutton, Scott
    Tatlock, John
    Verhelle, Dominique
    Wang, Fen
    Wells, Peter
    Wythes, Martin
    Yamazaki, Shinji
    Yip, Brian
    Yu, Xiu
    Zehnder, Luke
    Zhang, Wei-Guo
    Rollins, Robert A.
    Edwards, Martin
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (18) : 8306 - 8325
  • [39] Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival
    Karlowee, Vega
    Amatya, Vishwa Jeet
    Takayasu, Takeshi
    Takano, Motoki
    Yonezawa, Ushio
    Takeshima, Yukio
    Sugiyama, Kazuhiko
    Kurisu, Kaoru
    Yamasaki, Fumiyuki
    PATHOBIOLOGY, 2019, 86 (2-3) : 152 - 161
  • [40] Enhancer of Zeste Homolog 2 (EZH2) modulation in either embryonal or PAX3-FOXO1 alveolar rhabdomyosarcoma shows different anti-tumoral effects
    Rota, R.
    Carcarino, E.
    De Salvo, M.
    Adesso, L.
    Ciarapica, R.
    Marquez, V. E.
    Mai, A.
    Puri, P. L.
    Palacios, D.
    Locatelli, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S109 - S110